Aachen smoking cessation and harm reduction (ASCHR) trial study protocol – scientific evaluation of a psychological-telemedical counseling concept for smoking cessation in patients with vascular diseases
BMC Public Health, vol. 24, pp. 2695
Abstract
BACKGROUND: Smoking is a major risk factor of cardiovascular diseases, notably peripheral arterial disease (PAD). Despite this link, research on smoking cessation interventions in PAD patients remains scarce and inconclusive regarding the efficacy of such interventions. Therefore, elucidating it is crucial and should address both individuals who smoke that are motivated to quit and individuals who smoke heavily lacking the motivation to quit. METHODS/DESIGN: The Aachen Smoking Cessation and Harm Reduction (ASCHR) trial is a prospective randomized controlled study (RCT) on the benefits of telemedical-psychological support for smoking cessation in patients with PAD, funded by the "Innovation Fund" of the Joint Federal Committee in Germany. This trial aims to scientifically assess the efficacy, feasibility, acceptance, and efficiency of a multi-stage smoking cessation program based on the recommendations of the German guideline for smoking cessation tailored to patients with PAD, compared to a control group receiving no intervention. Central to the program is psychological counseling utilizing motivational interviewing techniques, delivered through telemedicine via video consultations. The primary endpoint of the ASCHR trial is the smoking cessation rate after 8 months of intervention, with a secondary endpoint evaluating sustained abstinence at a further 6 months follow-up. Smoking cessation is defined as a carbon monoxide level in exhaled air of less than 6 ppm. We hypothesize that the group receiving the multi-stage cessation program will yield a cessation rate at least 10 percentage points higher than that of usual care. Anticipating a dropout rate of around 35%, the planned sample size is at least N = 1032 study participants. DISCUSSION: Should the trial demonstrate significant positive outcomes, efforts should be made to integrate the program into routine care in Germany, potentially offering a promising base for future smoking cessation support among PAD patients.
Authors 9
-
Sebastian Scheliga corresponding Aachen Department of Psychiatry, Psychotherapy and Psychosomatics Faculty of Medicine
Affiliation as printed
Department of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, RWTH Aachen University, Aachen, Germany. sscheliga@ukaachen.de
Department of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, RWTH Aachen University, Aachen, Germany
-
Affiliation as printed
Department of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, RWTH Aachen University, Aachen, Germany
-
Affiliation as printed
Clinic for Vascular Medicine, Klinik Für Angiologie, HELIOS Klinik Krefeld, Lutherplatz 40, Krefeld, 47805, Germany
Clinic for Vascular Medicine, Klinik Für Angiologie, HELIOS Klinik Krefeld, Lutherplatz 40, Krefeld, 47805, Germany. knut.kroeger@helios-gesundheit.de
-
Affiliation as printed
Institute for Medical Informatics, RWTH Aachen University, Aachen, Germany
-
Affiliation as printed
ZTG Center for Telematics and Telemedicine GmbH, Hagen, Germany
-
Affiliation as printed
ZTG Center for Telematics and Telemedicine GmbH, Hagen, Germany
-
Affiliation as printed
ZTG Center for Telematics and Telemedicine GmbH, Hagen, Germany
-
Affiliation as printed
Department of General and Visceral Surgery, Catholic Hospital Dortmund West, Dortmund, Germany
-
Affiliation as printed
Department of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, RWTH Aachen University, Aachen, Germany
Cited by 1 stored of 1
1 result
No patents citing this paper on Lens.org (checked 2026-10-06).
References 18
-
W4210590551details pending0citations
18 results